Objective-Dystrophin, the missing or defective protein in Duchenne muscular dystrophy, is expressed not only in muscle cells but also in vascular endothelial cells (ECs). In this study, we assessed the effects of dystrophin deficiency on the angiogenic capacities of ECs. Approach and Results-We isolated vascular ECs from mdx mice, the murine equivalent of Duchenne muscular dystrophy in humans, and wild-type controls, and we found that mdx-derived ECs have impaired angiogenic properties, in terms of migration, proliferation, and tube formation. They also undergo increased apoptosis in vitro compared with wild-type cells and have increased senescence-associated β-galactosidase activity. Mdx-derived ECs also display reduced ability to support myoblast proliferation when cocultured with satellite cell-derived primary myoblasts. These endothelial defects are mirrored by systemic impairment of angiogenesis in vivo, both on induction of ischemia, stimulation with growth factors in the corneal model and matrigel plug assays, and tumor growth. We also found that dystrophin forms a complex with endothelial NO synthase and caveolin-1 in ECs, and that NO production and cGMP formation are compromised in ECs isolated from mdx mice. Interestingly, treatment with aspirin enhances production of both cGMP and NO in dystrophic ECs, whereas low-dose aspirin improves the dystrophic phenotype of mdx mice in vivo, in terms of resistance to physical exercise, muscle fiber permeability, and capillary density. Conclusions-These findings demonstrate that impaired angiogenesis is a novel player and potential therapeutic target in Duchenne muscular dystrophy. (Arterioscler Thromb Vasc Biol. 2013;33:2867-2876.) (S.S., M.C.). The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
I n Duchenne muscular dystrophy (DMD), the protein dystrophin, which serves as a link between cytoskeletal actin and the extracellular matrix, is missing or defective. 1, 2 Dystrophin expression is not limited to muscle tissues but is present in many other cell types, including endothelial cells (ECs). 3 The physiological importance of dystrophin in the vascular endothelium is demonstrated by the fact that mdx mice, the murine equivalent of DMD in humans, have vascular abnormalities that impair blood flow. This occurs through lower NO-dependent flow (shear stress)-induced endothelium-dependent dilation, reduced endothelial NO synthase (eNOS) and neuronal NOS expression, and decreased vascular density. [3] [4] [5] [6] [7] Based on this evidence, it has been proposed that the dystrophic skeletal muscle works in a condition of functional ischemia, determined by a mismatch between metabolic demand and blood flow supply, and that such condition is required for, and an essential cause of, muscle damage in mdx mice. 7, 8 The functional importance of deficient vascularization in the setting of muscular dystrophy has been confirmed by the demonstration that FMS-like tyrosine kinase-1 (Flt-1) haploinsufficiency ameliorates the dystrophic phenotype of mdx mice. 9 Flt-1 is a decoy receptor for vascular endothelial growth factor (VEGF), a prototypical angiogenic agent, and Flt-1 heterozygous knockout (Flt-1(+/−)) mice have increased EC proliferation and vascular density. 10 Interestingly, mdx:Flt-1(+/−) adult mice not only have increased muscle blood flow and capillary density compared with mdx mice but also display decreased fibrosis, calcification, and membrane permeability and increased force production. 9 Additional evidence of an interdependent relationship between angiogenesis and muscular dystrophy is provided by the recent finding that, in mdx mice, reducing angiogenesis by ablating the MMP-2 gene results in impaired growth of regenerating muscle fibers. 11 These data suggest that increasing the vasculature in DMD may ameliorate the histological and functional phenotypes associated with this disease and that, for an effective therapy of DMD, both the muscle and the vasculature should be addressed. 9 In this study, we used 4 distinct experimental models to demonstrate that angiogenesis is systemically impaired in vivo in mdx mice. Such impairment depends on the reduced angiogenic properties of the EC compartment, as indicated by the fact that, on stimulation with growth factors, mdxderived ECs have reduced ability to migrate, proliferate, and form tubular-like structures in vitro. They also have reduced ability to stimulate the proliferation of myogenic precursor cells, when cocultured with satellite cell-derived primary myoblasts. We also demonstrate that dystrophic ECs have impaired ability to produce NO and form cGMP, compared with wild-type ECs, and that such impairment may be rescued by treatment with low-dose aspirin. Low-dose aspirin also ameliorates the phenotype of mdx mice in vivo, by increasing the vascular density of the dystrophic skeletal muscle, reducing muscle fiber permeability, and improving resistance to physical exercise.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Systemic Impairment of In Vivo Angiogenesis in mdx Mice
To fully assess the angiogenic properties of mdx mice, we used 4 distinct experimental models, which encompass multiple aspects of in vivo angiogenesis in various organs and tissues.
First, we used the hindlimb ischemic model 12 and found significant impairment of ischemia-induced angiogenesis in mdx mice compared with controls. In particular, Laser Doppler perfusion imaging demonstrated a progressive increase in the blood flow of ischemic hindlimbs in wild-type mice, with significant differences seen at day 28 compared with days 7 and 14 after surgery (P<0.01; Figure 1A ). In contrast, there was no significant increase in the hindlimb blood perfusion of mdx mice during the 28 days of follow-up after ischemia. As a result, at day 28 after surgery, the Doppler flow ratio was significantly reduced in mdx mice in comparison with the wild-type group (0.37±0.12 versus 0.97±0.10; P<0.01; Figure  1A ). Likewise, capillary density at day 28 after surgery was significantly higher in the adductor muscle of wild-type mice versus mdx mice (555.7±51.2 versus 332.4±72.1 capillaries/ mm 2 ; P<0.001; Figure 1B and 1C).
Next, we used the corneal model of angiogenesis. The cornea is a nonvascularized tissue, thus it is commonly used to study the ability of a given molecule to induce neoangiogenesis. We implanted pellets containing VEGF, a prototypical angiogenic factor, in the corneas of mdx mice and wild-type animals. As expected and consistent with previous findings in the literature, 13 pellets containing VEGF induced a robust angiogenic response in the cornea of wild-type animals, as detected by bandeiraea simplicifolia lectin fluorescent staining 6 days after pellet implantation ( Figure 1D ). In contrast, VEGF-induced corneal neovascularization was strikingly reduced in mdx mice ( Figure 1D ). We performed a comprehensive quantification of prototypical parameters of corneal neovascularization and found that the number of vessels per cross-section (62.2±18.3 versus 130.2±25.4; P<0.001; Figure  1E ), the average length of the neovessels (0.69±0.11 versus 0.23±0.05 mm; P<0.001; Figure 1F ), and the circumferential extent of the neovasculature (52.5 versus 112.9±8.5 degrees; P<0.001; Figure 1G ) were significantly reduced in mdx mice compared with wild-type controls.
We also used the in vivo matrigel subcutaneous angiogenic assay. 14 Matrigel-containing VEGF was injected into the subcutaneous space along the dorsal midline of mdx mice and wild-type controls. Matrigel plugs were dissected and analyzed 14 days after implantation. As expected, the matrigel plugs containing VEGF that were implanted in wild-type mice exhibited a high number of vessels/field (78.2±14.3). In contrast, the number of neovessels/field was significantly lower in the matrigel plugs that were implanted in mdx mice (32.2±8.5; P<0.01; Figure 1H ).
Finally, we used a model of tumor growth. 15 Lewis lung carcinoma cells were injected subcutaneously in the proximal dorsal midline of mdx mice and wild-type controls. Tumor growth was measured every other day during a period of 20 days on tumor implantation. At the end of the follow-up period, tumor volume was significantly lower in mdx mice compared with controls (7015.3±1421.2 versus 11 052.8±1856.2 mm 3 ; P<0.01; Figure 1I ). Also, the tumors that had grown in mdx mice had a significantly lower number of vessels/cross-section than those that has grown in control animals (28.3±2.8 versus 55.2±5.8 vessels/cross-section; P<0.001; Figure 1J ).
To assess the proliferative index of the endothelium of mdx mice in vivo, we looked at the expression of the integrin αVβ3 in the mouse model of hindlimb ischemia. Among several integrins, αVβ3 is unique because this molecule is expressed exclusively by the angiogenic endothelium, whereas resting ECs do not display this integrin. Indeed, αVβ3 expression is indispensable for proliferation during angiogenesis. 16 Ten days after induction of ischemia, abundant αVβ3-positive ECs were discernible in the vasculature of regenerating muscles of wild-type mice, indicating an active angiogenic response of the wild-type endothelium to ischemia. Compared with these mice, the vasculature of ischemic muscles of mdx animals was instead substantially poorer in terms of αVβ3-positive cells ( Figure Ia in the online-only Data Supplement). We also performed a semiquantitative analysis of αVβ3 expression, which confirmed a significant decrease of the expression Taken together, these data provide strong evidence that angiogenesis is impaired in mdx mice, and that such impairment is not limited to the skeletal muscle, but instead is a systemic phenomenon.
EC Defects in mdx Mice
The corneal model of angiogenesis, the in vivo matrigel angiogenic assay, and the tumor model of angiogenesis demonstrate that, in mdx mice, angiogenesis is impaired also in the presence of VEGF stimulation and tumor growth. These findings suggest that deficient angiogenesis in mdx mice does not depend on the lack of appropriate angiogenic stimuli. To further explore this issue, we measured local levels of VEGF in the skeletal muscle of mdx and wild-type mice after hindlimb ischemia, based on the notion that VEGF is physiologically upregulated in skeletal muscle on induction of ischemia. 17 We found that, in mdx mice, ischemia-induced VEGF upregulation occurs normally and does not differ from that observed in wildtype controls ( Figure II in the online-only Data Supplement).
Although impairment of other angiogenic molecules necessary for the assembly of vascular unit cannot be excluded, the demonstration that VEGF production in response to ischemia is normal in mdx mice indicates that most likely the impairment of angiogenesis in these animals does not depend on insufficient production of angiogenic factor(s), suggesting instead that the problem may lie within the EC compartment. To test this hypothesis, we isolated ECs from the inguinal adipose tissues of mdx mice and wild-type controls. 18 After isolation, ECs were cultured under rigorously standardized conditions and used for the following set of in vitro assays. First, we performed a migration monolayer denudation assay 13 and found that the distance migrated, relative to untreated cells, was significantly reduced in ECs derived from mdx mice compared with those derived from wild-type controls (1.51±0.6 versus 2.85±0.5; P<0.01; Figure 2A ). Next, we performed a cell proliferation MTT assay 13 and found that ECs derived from mdx mice had significant impairment of proliferation compared with nondystrophic ECs (0.48±0.12 versus 0.883±0.06 optical density; P<0.01; Figure 2B ). Then, we determined that ECs derived from mdx mice had significantly increased apoptosis compared with nondystrophic ECs (P<0.05; Figure 2C ). Senescenceassociated β-galactosidase activity is determined by the overexpression and accumulation of endogenous lysosomal β-galactosidase specifically in senescent cells and is a widely used biomarker for senescent and aging cells. 19 We found significantly increased senescence-associated β-galactosidase Figure 2D ). Finally, we used a tube formation assay and found that the number of capillary-like structures was significantly lower in the assays containing mdx-derived ECs compared with those containing ECs isolated from wildtype mice (7.3±1.5 versus 10.6±1.2; P<0.05; Figure 2E ).
It is known that ECs interact, both directly and indirectly, with myoblasts and promote proliferation of myogenic precursor cells. 9 Because this phenomenon may be important in the setting of muscular dystrophy, we examined whether ECs isolated from mdx mice have impaired ability to support myoblast proliferation compared with nondystrophic ECs. Accordingly, ECs isolated from mdx mice or control mice were cocultured with satellite cell-derived primary myoblasts, as previously described. 8 In all cases, satellite cell-derived primary myoblasts were from wild-type mice. After 3 days of culture in myoblast growth media, we quantified the number of desminpositive cells, which is representative of myoblast proliferation and survival. The number of desmin-positive cells detected in the coculture assays was compared with that observed in cultures containing myoblasts alone. This analysis demonstrated that the relative number of desmin-positive cells was significantly lower in the assays containing ECs isolated from mdx mice compared with those containing ECs isolated from wildtype animals (1.15±0.11 versus 1.71±0.32; P<0.01; Figure 2F ).
Reduced Production of NO and Formation of cGMP in the ECs of mdx Mice
Previous data in the literature indicate that the expression of eNOS is lower in the arteries of mdx mice compared with . Angiogenic (and myogenic) defects in the endothelial cells (ECs) of mdx mice. ECs were isolated from the adipose tissue of mdx mice and wild-type controls. A, Migration was significantly reduced in ECs derived from mdx mice (n of cell lines=5) compared with controls (n of cell lines=5). B, A cell proliferation assay shows that ECs derived from mdx mice (n of cell lines=5) have impaired proliferation compared with ECs derived from wild-type animals (n of cell lines=5). C, ECs derived from mdx mice had significantly increased apoptosis compared with nondystrophic ECs. D, Senescence-associated β-galactosidase (SA-βgal) activity was significantly increased in ECs isolated from mdx mice compared with wild-type animals. E, Tube formation assay demonstrating significantly lower number of capillary-like structures in the assays containing mdx-derived ECs (no. of cell lines=5) compared with those containing ECs isolated from wild-type mice (no. of cell lines=5). F, The number of desmin-positive cells was significantly lower when satellite cell-derived primary myoblasts were cocultured with ECs isolated from mdx mice (no. of cell lines=5) compared with ECs isolated from wild-type mice (no. of cell lines=5).
controls and that this results in impaired NO-dependent arterial dilation. 5 Here, we tested the hypothesis that ECs isolated from mdx mice have reduced ability to produce NO. To test this hypothesis, we assessed citrulline formation, which is representative of NOS activity, in ECs and found significant lower levels of L-[ 3 H]-citrulline in the supernatant of culture dishes containing dystrophic ECs than in those containing wild-type ECs (7.2±2.1 versus 14.5±1.2 fmol/well; P<0.01; Figure 3A ). We also assessed the accumulation of cGMP in ECs because cGMP is both the second messenger of NO in many biological systems and a sensitive marker of intracellular NO formation. 20 We found significantly lower intracellular levels of cGMP in dystrophic ECs compared with control cells (2.85±0.5 versus 4.9±0.2 pmol/well; P<0.01; Figure 3B ).
Association of Dystrophin With eNOS and Cav-1 in ECs
To bring insights on how the lack of dystrophin causes reduced synthesis of NO in ECs, we studied the association of eNOS with dystrophin in ECs isolated from wild-type mice and also looked whether dystrophin and eNOS form a complex with Cav-1 in wild-type ECs because Cav-1 is the principal protein of caveolae in ECs, and it is well known that eNOS is active when located in the caveolae. 21 For these experiments, total protein extract was obtained from ECs isolated from wild-type mice and immunoprecipitated with an antidystrophin antibody. Total proteins and immunoprecipitated proteins were then analyzed by Western blot using antibodies against dystrophin, Cav-1, and eNOS. We found increased levels of eNOS and Cav-1 in proteins immunoprecipitated with an antidystrophin antibody compared with total protein extract ( Figure 4 ), indicating that dystrophin forms complexes with eNOS and Cav-1 in ECs.
Aspirin Has Multiple Beneficial Effects on the Angiogenic (and Myogenic) Properties of Dystrophic ECs In Vitro
Aspirin is able to enhance NO release from vascular ECs and has a protective role on ECs via the NO-cGMP pathway. 22 For these reasons, we tested the hypothesis that treatment with aspirin may increase the ability of dystrophic ECs to produce NO and form cGMP.
Citrulline synthesis was measured in the protein extracts of ECs isolated from mdx mice and wild-type mice and treated with various concentrations of aspirin or with control vehicle. These studies demonstrated that treatment with aspirin increases eNOS activity in both dystrophic and wild-type ECs in a concentration-dependent manner ( Figure 5A ). In particular, treatment of dystrophic ECs with 100 μmol/L aspirin increased L-[ 3 H]-citrulline levels to 12.5±0.7 fmol/well compared with 7.1±0.3 fmol/well detected in dystrophic ECs treated with vehicle control (P<0.05). Significantly higher levels of L-[ 3 H]citrulline were measured in the supernatant of dystrophic ECs treated with progressively higher concentrations of aspirin (16.1±0.2 fmol/well in cells treated with 300 μmol/L aspirin, P<0.01; 22.5±0.3 fmol/well in cells treated with 500 μmol/L aspirin, P<0.001). In this assay, aspirin-induced citrulline formation was depressed completely by the l-arginine antagonist L-NG-nitroarginine methyl ester, demonstrating that the observed effect was NO dependent ( Figure 5A ). Treatment with aspirin also increased the intracellular levels of cGMP in dystrophic and wild-type ECs compared with cells treated with vehicle control. Such effect was already significant (P<0.01) at aspirin concentrations (100 μmol/L) similar to those used for cardiovascular protection ( Figure  5B ). Progressively higher levels of cGMP were detected in dystrophic ECs treated with higher concentrations of aspirin . Association of dystrophin with endothelial NO synthase (eNOS) and caveolin-1 (Cav-1) in endothelial cells (ECs). ECs isolated from wild-type mice were used for total protein extraction and immunoprecipitation with an antidystrophin antibody. Western blot analysis showed increased levels of phosphorylated eNOS and Cav-1 in immunoprecipitated proteins compared with total protein extract. December 2013 (7. 0±0.5 pmol/well in cells treated with 300 μmol/L aspirin, P<0.01; 10.8±0.7 pmol/well in cells treated with 500 μmol/L aspirin, P<0.001), demonstrating that the observed effect is concentration dependent. To demonstrate that aspirin-induced cGMP accumulation was NO dependent, cells were preincubated with the NO scavenger phenyl-tatramethylimidazolineoxyl-1-oxyl-3-oxide which resulted in complete inhibition of endothelial cGMP stimulation ( Figure 5B ).
NO significantly contributes to the prosurvival/proangiogenic program of the vascular endothelium via eNOS activation and cGMP-dependent gene transcription. 20 Based on this concept and the evidence that aspirin enhances NO production and cGMP formation in dystrophic ECs, we tested the hypothesis that the impaired angiogenic ability that we observed in the ECs isolated from mdx mice may be rescued by treatment with aspirin. Thus, the assays presented in Figure  2 were repeated in the presence of aspirin supplementation (500 µmol/L). We found significant amelioration in the ability of aspirin-treated dystrophic ECs to migrate (P<0.01), proliferate (P<0.01), and form tubes (P<0.01) compared with cells treated with vehicle ( Figure 5C-5E ). Importantly, on treatment with 500 µmol/L aspirin, ECs isolated from mdx mice also exhibited significantly increased ability to support myoblast proliferation (P<0.01; Figure 5F ).
Beneficial Effects of Long-Term Treatment With Low-Dose Aspirin in mdx Mice In Vivo
Based on the in vitro findings outlined above, we tested the hypothesis that treatment with cardiovascular protection doses of aspirin may be beneficial in the setting of muscular dystrophy. Mdx mice were treated with daily low doses of aspirin (10 mg/kg per day), in drinking water for 7 months. An additional set of mdx mice received regular water and were used as controls. The dose that we used was chosen using interspecies conversion factors for equal body surface between humans and mice and corresponds to the range of low-dose Figure 5 . Beneficial effects of aspirin on the endothelial cells (ECs) of mdx mice. A, Aspirin increased endothelial NO synthase (eNOS) activity in a concentration-dependent manner in ECs derived from mdx and wild-type mice (n of cell lines=5); aspirin-induced citrulline formation was completely depressed by the l-arginine antagonist L-NG-nitroarginine methyl ester (L-NAME). B, Aspirin increased in a concentration-dependent fashion the intracellular levels of cGMP in dystrophic and wild-type ECs (n of cell lines=5); in cells preincubated with the NO scavenger phenyl-tatramethylimidazolineoxyl-1-oxyl-3-oxide (PTIO) there was a significant inhibition of endothelial cGMP stimulation by aspirin. C-E, Aspirin significantly ameliorated the ability of dystrophic ECs (n of cell lines=5) to migrate (P<0.01), proliferate (P<0.01), and form tubes (P<0.01) compared with cells treated with vehicle. F, On treatment with aspirin, ECs isolated from mdx mice (n of cell lines=5) had increased ability to support myoblast proliferation (P<0.01).
aspirin used for the prevention of cardiovascular diseases in humans. 23 Animals were 4 weeks old at the beginning of the experiments and 8 months old at the end of treatment. At this time point, mice were then challenged on a treadmill and running time, maximal speed, and distance covered were determined. Mdx mice treated with aspirin were able to run on the treadmill for a significantly longer period of time compared with mdx mice treated with control (17.6±1.2 versus 9.9±1.9 minutes; P<0.001; Figure 6A ). Likewise, the maximum speed reached on the treadmill was significantly higher in the group of aspirin-treated mice than in the group of control-treated animals (20.1±0.4 versus 14.7±1.0 m/min; P=0.001; Figure  6B ). Finally, mice treated with aspirin were able to cover a significantly greater distance than mice treated with control (162.0±7.3 versus 86.5±19.9 meters; P<0.001; Figure 6C ).
After completion of the treadmill experiments, mice were euthanized and the adductor and tibialis anterior muscles were harvested. At the histological level, we first assessed the effect of aspirin treatment on vascular density. Fluorescent staining with bandeiraea simplicifolia-lectin demonstrated significantly higher number of capillaries both in the adductor and in the tibialis anterior muscles of mdx mice treated with aspirin compared with those treated with control (347.3±18.1 versus 218.6±25.3 capillaries/cm 2 , P<0.001 and 344.5±17.8 versus 246.5±22.3 capillaries/cm2, P<0.01, respectively; Figure 7A and 7B). Next, we determined the number of regenerating myofibers, identified by the presence of centrally located nuclei. We found that the adductor and tibialis anterior muscles of mdx mice treated with aspirin had a significantly higher percentage of regenerating fibers compared with mdx mice treated with control (52.5±4.2% versus 36.3±2.1%, P<0.01 and 57.5±7.3% versus 46.1±3.2%, P<0.05; Figure 7C and 7D). We also assessed myofiber membrane permeability, by measuring Evans blue dye uptake, and found that the tibialis anterior muscles of mdx mice treated with control exhibited a significant increase in the percentage of Evans blue dye-positive myofibers compared with mdx mice treated with aspirin (2.6±1.8% versus 13.3±0.9%; P<0.001; Figure 7E and 7F). We also evaluated the extent of fibrosis by Van Gieson staining and observed significantly less fibrosis in mice treated with aspirin compared with controls (data not shown).
Discussion
Functional ischemia, impaired vasodilatation in response to flow, reduced NO production, and various types of vascular abnormalities have been described in the setting of muscular dystrophy both in humans and in mice. [3] [4] [5] [6] [7] [8] [9] Recent work demonstrates that improving vascular density and promoting angiogenesis might be beneficial in muscular dystrophy. 9, 10, 20, 24 For these reasons, some studies have tested the ability of angiogenic growth factors to improve the dystrophic phenotype in experimental models of DMD. 25, 26 However, no attention has been paid to the possibility that, in muscular dystrophy, the vascular endothelium might be less responsive to angiogenic stimuli and growth factors and that this deficit might contribute to the development and progression of muscle damage and degeneration.
In this study, we demonstrate that angiogenesis is significantly impaired in mdx mice and that such impairment is detectable in various organs and tissues and under different experimental conditions. We have reported previously that mdx mice exhibit a normal angiogenic response to hindlimb ischemia and even display increased arteriole length density. 27 However, in that study, we used young (8-week-old) mdx mice, which still have very robust regenerative capacities and are not fully representative of the human dystrophic disease. 28 In contrast, in the present study, we used 6-month-old mdx mice, which display more advanced-stage disease, a condition that might also negatively affect angiogenesis. In addition, in our previous study, we only evaluated angiogenesis in the hindlimb ischemic model, without assessing the angiogenic properties of mdx mice at the systemic level. In the present study, we demonstrate that angiogenesis is impaired also in the corneal model, the matrigel angiogenic assay, and the tumor model, thus providing evidence that this phenomenon occurs at the systemic level, is not limited to the skeletal muscle, and does not depend on the peculiar pathobiological environment of the dystrophic musculature. In addition, the fact that angiogenesis is impaired on implantation of pellets or matrigel-containing VEGF, and also during tumor growth, Figure 6 . Long-term treatment with low doses of aspirin improves resistance to physical exercise in mdx mice. A, Mdx mice (n=20) treated for 7 months with 10 mg/kg per day of aspirin in drinking water were able to run on a treadmill for a significantly longer time compared with mdx mice receiving regular drinking water (n=20; P<0.001). They also reached (B) a significantly higher maximal speed (P=0.001) and (C) covered a significantly greater distance than mice receiving regular drinking water (P<0.001).
suggests that the cause of this impairment is not the lack of appropriate angiogenic stimulation or the reduced expression of growth factors. This is also confirmed by the demonstration that, on induction of ischemia, VEGF upregulation occurs normally in mdx mice. Based on these observations, we investigated the hypothesis that the problem lies within the EC compartment and performed experiments that clearly demonstrate that vascular ECs of mdx mice have reduced ability to respond to angiogenic stimulation in terms of migration, proliferation, and tube formation.
The biological foundation of our findings is that dystrophin is physiologically expressed in ECs and is important for proper function of the vascular endothelium. [3] [4] [5] [6] [7] 9 Although the exact role of dystrophin in ECs is not well understood, it has been hypothesized that dystrophin is essential for eNOS to translocate to the caveolae, 29 and several reports have shown that flow-induced dilation and arterial shear-stress mechanotransduction are significantly impaired in the absence of dystrophin. [3] [4] [5] Here, we show that, in wild-type ECs, dystrophin forms a complex with cav-1 and eNOS, and that NO production and cGMP formation are significantly impaired in ECs derived from mdx mice. We also show that NO production in mdx-derived ECs may be enhanced by treatment with aspirin and this corresponds to amelioration of the angiogenic deficits displayed in vitro by these cells. These findings are relevant to muscular dystrophy because, in recent years, NO has emerged as an important messenger not only for angiogenesis but also for myogenesis, especially when this process is required for muscle repair after acute and chronic skeletal muscle injury, as in muscular dystrophy. 30 If a dysfunctional EC compartment participates to the mechanisms underlying deficient angiogenesis in mdx mice, then there is a need for revising and improving the concept that angiogenic growth factors may be useful to improve the dystrophic phenotype in the setting of muscular dystrophy. Indeed, although it has been reported that VEGF may increase capillary density in the dystrophic skeletal muscle, 25, 26 our findings suggest that treatments that protect the endothelium and correct endothelial dysfunction by donating NO may be potentially beneficial and should be considered as novel therapeutic strategies, alone or in combination with growth factors, in muscular dystrophy. In this respect, a novel finding of this Long-term treatment with low doses of aspirin increases capillary density, reduces membrane permeability, and increases the number of regenerating fibers in mdx mice. A and B, In mdx mice treated with aspirin, we found, compared with mdx mice receiving regular drinking water, a higher number of capillaries, quantified by bandeiraea simplicifolia-lectin staining, both in the adductor muscle and in the tibialis anterior muscle with statistically significant differences (P<0.001 and P<0.01, respectively). C and D, The number of regenerating myofibers, identified by the presence of centrally located nuclei, was increased in the adductor muscles and the tibialis anterior muscles of mdx mice treated with aspirin compared with mdx mice receiving regular drinking water, with statistically significant differences (P<0.01 and P<0.051, respectively). E and F, The number of Evans blue dye-positive muscle fibers was significantly reduced in the tibialis anterior muscle of mdx mice treated with aspirin compared with mdx mice receiving regular drinking water (P<0.001). study is that low-dose aspirin ameliorates the dystrophic phenotype in mdx mice. Although we did not conduct a formal preclinical therapeutic study, these data are important because they provide proof of the concept that an agent that protects the vascular endothelium and increases NO production in ECs, such as low-dose aspirin, may have beneficial effects on the dystrophic phenotype of the skeletal muscle.
About the mechanisms through which aspirin exerts its beneficial effects in mdx mice, our data suggest that enhancement of NO production and intracellular cGMP accumulation in dystrophic ECs may be an important issue. This is consistent with new evidence supporting the use of NO-donating drugs as therapeutic agents for muscle repair and muscular dystrophy. 8, [30] [31] [32] It is also consistent with other findings demonstrating that enhancing cGMP signaling improves contractile performance and myocardial metabolic status in the dystrophindeficient heart. 32 It has been shown that NO-donating drugs correct functional ischemia in the setting of muscular dystrophy both in animal models and in humans, by restoring normal blood flow regulation and response to vasoconstrictors. 8, 33 These effects are classically attributed to the role played by sarcolemmal neuronal NOS in the modulation of sympathetic vasoconstriction in exercising skeletal muscles. 8, 32 Our data demonstrate that, in the mdx mouse, NO production is deficient also in the EC compartment, thus supporting the concept that NO-donating drugs may also be useful to directly improve endothelial function, increase microvasculature recruitment, and enhance perfusion. 30 In addition, NO is a potent angiogenic factor, 20 and the fact that treatment with aspirin also ameliorates the angiogenic properties of dystrophic ECs in vitro and increases capillary density in vivo indicates that the beneficial effects of aspirin on the dystrophic phenotype of the skeletal muscle may be, at least in part, also mediated by angiogenesis, which would offer a protective mechanism for contraction-induced damage of the skeletal muscle. Finally, although our data demonstrate that endothelial defects in the mdx mouse are not limited to the muscle, but are present at the systemic level (ie, the cornea and the subcutaneous space), it is possible that aspirin treatment in vivo has beneficial effects on the dystrophic phenotype of the mdx muscle also for reasons that do not depend on angiogenesis or endothelial function. For instance, aspirin might have an effect on the cytokine milieu in the muscle and thus ameliorate endothelial dysfunction also in an indirect manner.
It has also been reported that increased capillary density and enhanced cGMP signaling in dystrophin-deficient animals lead to more stable and less degenerative fibers. 9, 33, 34 This is consistent with our observation of reduced myofiber membrane permeability in mdx mice treated with aspirin. About the positive effect of aspirin on the number of regenerating fibers in vivo, further studies are needed to understand whether this will be beneficial in the long term because enhanced regeneration may eventually result in exhaustion of the satellite cell population. However, our in vitro coculture assays show that aspirin improves the ability of ECs to support myoblast proliferation and survival. Because self-renewal capacities are critical to maintain the reserve pool of satellite cells, the fact that aspirin facilitates the interaction between ECs and myoblasts may suggest that treatment with aspirin not only promotes the formation of new myotubes but also supports the maintenance of the satellite cell population and thus warrants efficient tissue regeneration over time.
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